Professor Paolo Pozzilli, MB BS, MD
Professor of Diabetes and Clinical Research
Email: email@example.comTelephone: 020 7882 2482
Profile Paolo Pozzilli is Professor of Diabetes and Clinical Research at the Centre for Diabetes at Barts and The London School of Medicine & Dentistry, London, and Professor of Endocrinology & Metabolic Diseases at the University Campus Bio-Medico in Rome, Italy.
He qualified in Medicine at "Sapienza" University in Rome and specialized in Endocrinology and Metabolic Diseases at the same University. He has participated in 4 Biomed projects of the European Union and 3 NIH projects. He is Member of Ancillary Study Committee for the TRIGR Study (NIH project), Chairman of the IMDIAB Group and Deputy Chairman of the ACTION LADA Project (EU).
He coordinates the International PhD programme in Endocrinology and Metabolic Diseases between Queen Mary University of London, University Campus Bio-Medico in Rome and the University of Ulm, Germany.
He is Member Scientific Advisory Board of the Graduate School in Molecular Medicine, University of Ulm, Member Advisory Board of the International Diabetes Federation, Group for Diabetes in the Youth and Delegate for University Campus Bio-Medico, Permanent Conference of Rectors of the Italian Universities (CRUI).
He is currently the European Editor of Diabetes Metabolism Research & Reviews, John Wiley Publ.
He was the recipient of several awards including the Andrew Cudworth Memorial Prize of the British Diabetic Association (1986), the G.B. Morgagni Prize, Young Investigator Award of the European Association of Metabolism (1989), the SID Prize 1994 (Italian Society of Diabetes), the Karol Marcinkowski Medal of the "Poznan Academy of Medicine" Poland (1997), the Mary Jane Kugel Award, Juvenile Diabetes Research Foundation, USA (2003 and 2006) and the Diabetes Honoris Causa, Paulescu Foundation & Romanian Society of Diabetes (2007).
Member Advisory Board NAIMIT Project (EU)
Member of the Executive Committee of the International Centre
for the Study of Diabetes (CISD) (Rome)
Member Scientific Advisory Board, Graduate School in Molecular Medicine, University of Ulm
Member Advisory Board, International Diabetes Federation, Group for Diabetes in the Youth
Member Ethical Committee, University Campus Bio-Medico di Roma
Delegate for University Campus Bio-Medico, Permanent Conference of Rectors of the Italian Universities (CRUI)
Member Research Board, University Campus Bio-Medico di Roma
European Editor, Diabetes/Metabolism Research and Reviews
Member Editorial Board “The Endocrinologist”.
Research projects focus on the pathogenesis of type 1 diabetes (T1DM) taking advantage of a large database of DNA and sera from patients with T1DM and related auto immuno diseases.
Early diagnosis and prevention of beta-cell destruction in patients affected by T1DM and LADA (Latent autoimmune diabetes in adults) are among study priorities. Research focuses on the epidemiological, genetic and immunological aspects of diabetes associating with other diseases such as rheumatoid arthritis.
In collaboration with academic Institutions in Europe special attention is paid to intervention trials for protection of residual beta cell function in T1DM. More recently studies are ongoing on the use of immunomodulatory drugs at diagnosis at T1DM, thus offering novel approaches for treatment of this condition.
Studies are ongoing to generate insulin producing cells from adult mesenchymal stem cells. The project includes several steps from the establishment of the best conditions for the isolation and culture of mesenchymal stem cells obtained from abdominal fat to their proliferation and differentiation into different cell types such insulin producing cells as well as osteoblasts and condroblasts. These cells have been selected because they are easily obtainable in humans and may be applied safely in translational medicine.
A special link has been established with University Campus Bio-Medico in Rome, Italy, covering the Erasmus exchange programme for undergraduate medical students, a postgraduate PhD programme in Endocrinology and Metabolic Diseases and teacher exchange in Diabetes and Metabolic Diseases.
MSc, international PhD Programme in Endocrinology and Diabetes.
Modules taught: diabetes
Topics for PhD supervision:
Diabetes, autoimmunity, genetics, beta cell regeneration, immunotherapy of Diabetes.
Autoimmune and genetic aspects of diabetes, immunotherapy of type 1 diabetes, regeneration of beta cells.
Maddaloni E, Pozzilli P. Diabetes: the disease of the 10 D. 2017 Oct 26. doi: 10.1007/s12020-017-1454-7
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Sep 28;377(13):1228-1239.
Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Simó R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017 Dec 14;377(24):2337-2348.
Piemonte V, Capocelli M, De Santis L, Maurizi AR, Pozzilli P. A Novel Three-Compartmental Model for Artificial Pancreas: Development and Validation. Artif Organs. 2017 Dec;41(12):E326-E336.
Quercia S, Turroni S, Fiori J, Soverini M, Rampelli S, Biagi E, Castagnetti A, Consolandi C, Severgnini M, Pianesi M, Fallucca F, Pozzilli P, Brigidi P, Candela M. Gut microbiome response to short-term dietary interventions in reactive hypoglycemia subjects. Diabetes Metab Res Rev. 2017 Nov;33(8).
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657.
Strollo R, Vinci C, Napoli N, Pozzilli P, Ludvigsson J, Nissim A. Antibodies to post-translationally modified insulin as a novel biomarker for prediction of type 1 diabetes in children. Diabetologia. 2017 Aug;60(8):1467-1474.
Guglielmi C, Del Toro R, Lauria A, Maurizi AR, Fallucca S, Cappelli A, Angeletti S, Lachin JM, Pozzilli P. Effect of GLP-1 and GIP on C-peptide secretion after glucagon or mixed meal tests: Significance in assessing B-cell function in diabetes. Diabetes Metab Res Rev. 2017 Sep;33(6).
Soare A, Khazrai YM, Fontana L, Del Toro R, Lazzaro MC, Di Rosa C, Buldo A, Fioriti E, Maddaloni E, Angeletti S, Di Mauro A, Gesuita R, Skrami E, Tuccinardi D, Fallucca S, Pianesi M, Pozzilli P. Treatment of reactive hypoglycemia with the macrobiotic Ma-pi 2 diet as assessed by continuous glucose monitoring: The MAHYP randomized crossover trial. Metabolism. 2017 Apr;69:148-156.
Schloot NC, Pham MN, Hawa MI, Pozzilli P, Scherbaum WA, Schott M, Kolb H, Hunter S, Schernthaner G, Thivolet C, Seissler J, Leslie RD; Action LADA Group. Inverse Relationship Between Organ-Specific Autoantibodies and Systemic Immune Mediators in Type 1 Diabetes and Type 2 Diabetes: Action LADA 11. Diabetes Care. 2016 Nov;39(11):1932-1939.
Soare A, Del Toro R, Khazrai YM, Di Mauro A, Fallucca S, Angeletti S, Skrami E, Gesuita R, Tuccinardi D, Manfrini S, Fallucca F, Pianesi M, Pozzilli P. A 6-month follow-up study of the randomized controlled Ma-Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes. Nutr Diabetes. 2016 Aug 15;6(8):e222.
Maddaloni E, Cavallari I, De Pascalis M, Keenan H, Park K, Manfrini S, Buzzetti R, Patti G, Di Sciascio G, Pozzilli P. Relation of Body Circumferences to Cardiometabolic Disease in Overweight-Obese Subjects. Am J Cardiol. 2016 Sep 15;118(6):822-827.
Rizzo P, Pitocco D, Zaccardi F, Di Stasio E, Strollo R, Rizzi A, Scavone G, Costantini F, Galli M, Tinelli G, Flex A, Caputo S, Pozzilli P, Landolfi R, Ghirlanda G, Nissim A. Autoantibodies to post-translationally modified type I and II collagen in Charcot neuroarthropathy in subjects with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2017 Feb;33(2).
Amed S, Pozzilli P. Diagnosis of diabetes type in children and young people: challenges and recommendations. Lancet Diabetes Endocrinol. 2016 May;4(5):385-6.
Maddaloni E, D'Onofrio L, Pozzilli P. Frailty and geography: should these two factors be added to the ABCDE contemporary guide to diabetes therapy? Diabetes Metab Res Rev. 2016 Feb;32(2):169-75.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.
Strollo R, Vinci C, Arshad MH, Perrett D, Tiberti C, Chiarelli F, Napoli N, Pozzilli P, Nissim A. Antibodies to post-translationally modified insulin in type 1 diabetes. Diabetologia. 2015 Dec;58(12):2851-60.
Maddaloni E, Lessan N, Al Tikriti A, Buzzetti R, Pozzilli P, Barakat MT. Latent Autoimmune Diabetes in Adults in the United Arab Emirates: Clinical Features and Factors Related to Insulin-Requirement. PLoS One. 2015 Aug 7;10(8).
Khazrai YM, Buzzetti R, Del Prato S, Cahn A, Raz I, Pozzilli P. The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. J Diabetes Complications. 2015 May-Jun;29(4):599-606.
Signore A, Capriotti G, Chianelli M, Bonanno E, Galli F, Catalano C, Quintero AM, De Toma G, Manfrini S, Pozzilli P; Action LADA Group. Detection of insulitis by pancreatic scintigraphy with 99mTc-labeled IL-2 and MRI in patients with LADA (Action LADA 10). Diabetes Care. 2015 Apr;38(4):652-8.
Hernandez M, Mollo A, Marsal JR, Esquerda A, Capel I, Puig-Domingo M, Pozzilli P, de Leiva A, Mauricio D; Action LADA consortium. Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9. BMC Endocr Disord. 2015 Jan 9;15:1.
Lauria A, Barker A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C, Mauricio D, Nordwall M, Van der Schueren B, Mandrup-Poulsen T, Scherbaum WA, Weets I, Gorus FK, Wareham N, Leslie RD, Pozzilli P. BMI is an important driver of β-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children. Eur J Endocrinol. 2015 Feb;172(2):107-13.
Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, Pozzilli P; DEFEND Investigator Group.Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014 Oct;37(10):2746-54.
Barker A, Lauria A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C, Mauricio D, Nordwall M, Van der Schueren B, Mandrup-Poulsen T, Scherbaum WA, Weets I, Gorus FK, Wareham N, Leslie RD, Pozzilli P.Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes Obes Metab. 2014 Mar;16(3):262-7.
View all Paolo Pozzilli's Research Publications at: http://www.researchpublications.qmul.ac.uk